Patient value over patent value: the mandate for open-source oncology
GIST
Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents.
Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership. Access to this article via Institution of Civil Engineers Library is not available.
Liao, X. et al.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N.
Engl. J.
Med. 367 , 1596–1606 (2012).
Martling, A. et al.
Low-dose aspirin for PI3K-altered localized colorectal cancer. N.
Engl. J.
Med. 393 , 1051–1064 (2025).
Chia, J. W.
K. et al.
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol.
Hepatol. 10 , 198–209 (2025).
Yaqub, S. et al.
Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. J.
Clin. Oncol.
43 , LBA3511 (2025).
Clinical Editorial
Summary
Nature Reviews Clinical Oncology published a clinical update in Oncology on 26 Jun 2026.
The item focuses on Patient value over patent value: the mandate for open-source oncology.
Review the original article for the full source wording and details.